oncnursingnews1h
Addition of Concomitant TTFields Induces OS Benefit in Unresectable Pancreatic Cancer
The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...
oncnursingnews22h
FDA Approves First and Only Systemic Therapy for NRG1+ Lung, Pancreatic Cancers
Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or ...
oncnursingnews1d
LBS-007 Receives FDA Fast Track Designation for Acute Myeloid Leukemia
The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.
oncnursingnews2d
Lung Cancer Survival Improves, But Gaps in Biomarker Testing Remain
According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
oncnursingnews1d
FDA Grants Fast Track Designation to R289 for Lower-Risk MDS
Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
oncnursingnews1d
ERIC BLACKSTONE, MA
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...
oncnursingnews2d
Angee Kilmer, BSN, RN-BC
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...